Hepatitis B and C in peritoneal dialysis patients

Seminars in Nephrology

Volumn 22, Issue 4, 2002, Pages 351-360

  Puttinger, Heidi ^a   Vychytil, Andreas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

BLOOD TRANSFUSION; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; KIDNEY FAILURE; MEDICAL STAFF; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; VACCINATION; VIRAL CONTAMINATION; VIRUS TRANSMISSION;

CROSS INFECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS C; HUMANS; KIDNEY FAILURE; PERITONEAL DIALYSIS; PREVALENCE; RISK FACTORS; RNA, VIRAL;

EID: 0036070387     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Peritoneal dialysis fluid as a source of hepatitis antigen
2. Hepatitis and treatment of chronic renal failure by peritoneal dialysis
3. Continuous ambulatory peritoneal dialysis
4. Hepatitis B immunization in dialysis patients - Is it worthwhile?
5. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: Experience from Taiwan, an endemic area for hepatitis B
6. Viral hepatitis infection should be considered for evaluating uremic pruritus in continuous ambulatory peritoneal dialysis patients
7. Prevalence of hepatitis B and C in patients registered on the cadaver kidney transplant waiting list in Mexico
8. Hepatitis C virus infection among chronic dialysis patients in the south of France: A collaborative study
9. Hepatitis C infection among dialysis patients: A comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis
10. Prevalence of HCV antibodies in a uraemic population undergoing maintenance dialysis therapy and in the staff members of the dialysis unit
11. Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis
12. Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera
13. Prevalence of antihepatitis C antibodies in patients treated with continuous ambulatory peritoneal dialysis and hemodialysis
14. Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: Evaluation of some risk factors
15. Prevalence of antibodies against hepatitis C virus in a dialysis unit
16. Hepatitis C in chronic renal failure patients
17. Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center
18. Seroconversion to hepatitis C virus in dialysis patients: A retrospective and prospective study
19. Hepatitis-C virus (HCV) in peritoneal dialysis
20. Hepatitis C virus infection in renal dialysis patients in Glasgow
21. Comparison of three different tests for assessment of hepatitis C virus in dialysis patients
22. Prevalence of hepatitis C virus in dialysis patients in Spain
23. Prevalence and epidemiology of hcpatitis C infection in patients on peritoneal dialysis in France
24. Prevalence and risk factors for hepatitis C virus infection in continuous ambulatory peritoneal dialysis patients
25. Hepatitis C antibodies in patients on peritoneal dialysis: Prevalence and risk factors
26. Hepatitis C virus infections in dialysis centers in The Netherlands: A national survey by serological and molecular methods
27. HCV infection in haemodialysis and CAPD patients
28. CAPD: A control strategy to prevent spread of HCV infection in end-stage renal disease
29. Prevalence of antibodies to hepatitis C virus in patients on peritoneal dialysis - A multicenter study
30. Diffusion of HCV through peritoneal membrane in HCV positive patients treated with continuous ambulatory peritoneal dialysis
31. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: Evidence for environmental transmission
32. Absence of seroconversion to hepatitis C virus infection in CAPD patients
33. Epidemiology of viral hepatitis in dialysis centers: A national survey
34. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study
35. Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease
36. Prevalence of antibodies to hepatitis C in dialysis patients and transplant recipients with possible routes of transmission
37. Viral hepatitis in continuous ambulatory peritoneal dialysis patients in an endemic area for hepatitis B and C infection: The Taiwan experience
38. The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis
39. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection
40. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - An analysis of 309 sex partnerships
41. Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction
42. Detection of HCV RNA in saliva, urine, seminal fluid, and ascites
43. Hepatitis B surface antigen (HBsAg) in peritoneal fluid of HBsAg carriers undergoing peritoneal dialysis
44. Hepatitis B miniepidemic in a peritoneal dialysis unit
45. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid
46. Hepatitis C virus in chronic hemodialysis patients with non-A, non-B hepatitis
47. Decreased serum aminotransferase activity in patients with chronic renal failure: Impact on the detection of viral hepatitis
48. Liver disease in dialysis patients with antibodies to hepatitis C virus
49. Extrahepatic immunological manifestations of hepatitis C virus in dialysis patients
50. Host defenses and immunologic alterations associated with chronic hemodialysis
51. Influence of coexisting disease on survival on renal-replacement therapy
52. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy
53. Risk of death among chronic dialysis patients infected with hepatitis C virus
54. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States
55. Improved hepatitis B vaccination rates in ESRD patients in California
56. Efficacy of hepatitis B vaccination in patients on CAPD compared to patients on hemodialysis
57. Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients
58. Does the response to hepatitis B vaccination predict CAPD-associated infections?
59. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients
60. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration
61. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine
62. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination
63. Interferon treatment for chronic hepatitis C virus infection in uremic patients
64. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients
65. Secondary hyperparathyroidism exacerbation: A rare side-effect of interferon-alpha?
66. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - A pilot study
67. Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites
68. Peritoneal dialysis in liver disorders
69. Is HCV-infection another reason to opt for peritoneal dialysis in end-stage renal failure?